硼替佐米在不同剂量下治疗多发性骨髓瘤的Meta分析  

Meta-analysis of different doses of bortezomib in the treatment of multiple myeloma

作　　者：司霞[1] 宋荣景 陈月[1] 冯婉玉[1] 

机构地区：[1]北京大学人民医院药剂科,北京100044

出　　处：《中国临床药理学杂志》2016年第7期660-662,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的系统评价硼替佐米在不同剂量下治疗多发性骨髓瘤的疗效与安全性。方法检索Pub Med、Cochrane Library、Em Base、中国生物医学文献(CBM)、中国知网(CNKI)、万方和维普数据库中不同剂量硼替佐米治疗多发性骨髓瘤的随机对照研究(RCT)和观察性研究,用Rev Man 5.3软件进行Meta分析。结果纳入3个随机对照研究和8个队列研究,共625例患者。试验组(0.7~1.1 mg·m^(-2))硼替佐米治疗多发性骨髓瘤的有效率及完全缓解率与对照组(1.2~1.3 mg·m^2)比较差异无统计学意义(P>0.05)。试验组可以降低周围神经病变、带状疱疹和粒细胞减少的发生率(P<0.05)。结论减低剂量硼替佐米治疗多发性骨髓瘤与对照组疗效相似,安全性优于对照组。Objective To evaluate the efficacy and safety of different doses of bortezomib in patients with multiple myeloma（ MM）. Methods Retrived from Pub Med,Em Base,Cochrane Library,CBM,CNKI,VIP and Wan Fang database,randomized controlled trials（ RCTs） and observational studies about the efficacy and safety of bortezomib in the treatment of multiple myeloma were collected. Rev Man 5. 3 was applied for data analysis. Results A total of 3 randomized controlled trials and 8 cohort studies involving 625 patients were included. The results of Meta-analysis showed that there were no significant differences between the reduced dose group（ 0. 7- 1. 1 mg·m^-2） and the standard dose group（ 1. 2- 1. 3 mg·m^-2） in the effective rate and complete response（ CR）rate（ P〉0. 05）. In terms of safety,the results of RCTs and cohort studies showed that the incidences of peripheral neuropathy,herpes zoste and neutropenia were even lower in reduced dose group than those in standard dose group（（ P〈0. 05）. Conclusion Reduced dose group of bortezomib is as effective as and safer than standard dose group in the treatment of MM.

关 键 词：硼替佐米 多发性骨髓瘤 META分析 随机对照试验 观察性研究 

分 类 号：R979.1[医药卫生—药品]